Turning Point Brands (TPB) Could Be 33% Undervalued As Nicotine Pouch Growth Draws Focus

Turning Point Brands (TPB) is drawing fresh attention after recent commentary around its shift from traditional tobacco products to nicotine pouches, centered on the ALP and FRE brands and a new Louisville manufacturing facility.

See our latest analysis for Turning Point Brands.

At a share price of $87.37, Turning Point Brands has seen short term momentum pick up, with a 1 day share price return of 3.02% and a 90 day share price return of 21.08%. This is set against a year to date share price decline of 20.75% but supported by a 1 year total shareholder return of 20.68% and a very large 3 year total shareholder return of 271.31%, which suggests that recent nicotine pouch news is being weighed against an already strong multi year record.

If the shift toward nicotine pouches has caught your attention, it could be a good moment to widen your watchlist and check out 20 top founder-led companies

With Turning Point Brands posting a 1 year total shareholder return above 20% and trading at $87.37 against a published analyst price target of $130.00, the question arises: is there still value on the table, or is the market already pricing in future growth?

Most Popular Narrative: 32.8% Undervalued

Turning Point Brands' most followed valuation narrative pegs fair value at $130, well above the recent $87.37 close, framing the current price as a discount to that scenario.

The company's ability to grow its premium brands in high-margin niches (e.g., Stoker's MST and Zig-Zag) while maintaining strong customer loyalty and executing pricing actions, even as legacy segments decline, underpins stable or improving net margins and cash generation through industry transitions.

Read the complete narrative.

Want to see what underpins that $130 view? The narrative leans on brisk top line expansion, rising profitability, and a richer earnings multiple than the sector. Curious which specific growth and margin assumptions have to hold for that gap between $87.37 and $130 to make sense?

Result: Fair Value of $130 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Turning Point Brands still faces meaningful risks, including heavier reliance on Modern Oral nicotine pouches and potential regulatory or taxation changes that could quickly reshape that growth story.

Find out about the key risks to this Turning Point Brands narrative.

Another Take On Turning Point Brands' Valuation

The analyst narrative frames Turning Point Brands as 32.8% undervalued using earnings forecasts and a forward P/E of 26.8x. Yet on today’s numbers, the stock trades on a P/E of 30.5x, far above the global tobacco average of 12.4x and only slightly below peers at 31.3x. That leaves investors weighing whether the premium points to opportunity or stretches the margin for error.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Unsure how Turning Point Brands stacks up after reviewing all this data and narrative detail? Act promptly, consider both the potential and the concerns, and weigh the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Turning Point Brands?

If Turning Point Brands has sharpened your focus, do not stop here, use the Simply Wall St screener to spot other opportunities that fit your approach.

• Target resilient companies by reviewing the 73 resilient stocks with low risk scores that prioritise stability and controlled downside.
• Hunt for quality at a reasonable price by scanning the screener containing 19 high quality undiscovered gems that many investors may be overlooking.
• Strengthen your core holdings by filtering for the solid balance sheet and fundamentals stocks screener (47 results) that can better withstand financial pressure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com